Acurx Pharmaceuticals, Inc. (ACXP) Financial Statements (2024 and earlier)

Company Profile

Business Address 259 LIBERTY AVENUE
STATEN ISLAND, NY 10305
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

9/30/2023
MRQ
12/31/2022
12/31/2021
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments9,111,75112,958,846
Cash and cash equivalents9,111,75112,958,846
Prepaid expense264,955295,304
Total current assets:9,376,70613,254,150
Noncurrent Assets
TOTAL ASSETS:9,376,70613,254,150
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:2,061,685843,909
Employee-related liabilities508,343
Accrued liabilities626,61043,102
Other undisclosed accounts payable and accrued liabilities1,435,075292,464
Total current liabilities:2,061,685843,909
Noncurrent Liabilities
Total liabilities:2,061,685843,909
Equity
Equity, attributable to parent7,315,02112,410,241
Common stock11,62810,216
Additional paid in capital45,944,47838,948,334
Accumulated deficit(38,641,085)(26,548,309)
Total equity:7,315,02112,410,241
TOTAL LIABILITIES AND EQUITY:9,376,70613,254,150

Income Statement (P&L) (USD)

9/30/2023
TTM
12/31/2022
12/31/2021
Operating expenses(12,092,776)(12,814,200)
Operating loss:(12,092,776)(12,814,200)
Loss from continuing operations:(12,092,776)(12,814,200)
Loss before gain (loss) on sale of properties:(12,814,200)
Other undisclosed net income  66,503
Net loss available to common stockholders, diluted:(12,092,776)(12,747,697)

Comprehensive Income (USD)

9/30/2023
TTM
12/31/2022
12/31/2021
Net loss:(12,092,776)(12,747,697)
Comprehensive loss, net of tax, attributable to parent:(12,092,776)(12,747,697)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: